MAPCs are a population of bone marrow-derived adherent progenitor cells .
MAPCs have been shown to bypass the pulmonary capillary bed compared to larger MSCs after intravenous injection, leading to more cells contacting splenocytes .
Results demonstrated MAPCs
exhibited a more robust angiogenic protein release profile compared to MSCs in vitro.
When MAPCs are injected into a rat vein one day after injury, the rats recover more mobility and the ability to urinate on their own compared to rats without treatment or rats treated immediately with MAPCs.
One might assume that the MAPCs have this effect by converging on the injured area of the spinal cord and regrowing nerve cells.
A laboratory examination of the rodents' brains confirmed that those receiving the higher dose of MAPCs
had better brain function than those receiving the lower dose.
One group of animals was treated after the transplant with a combination of MAPCs
and a low-dose of an immunosuppressive drugs only.
One group of animals was treated after the transplantation with a combination of MAPCs
and short-term administration of low-dose immunosuppressive drug.
The researchers have isolated the MAPCs
from mice, rats, and humans, though for unknown reasons, they are able to do so in only 70% to 80% of people they test.
Dubbed "multipotent adult progenitor cells" (MAPCs
), the adult stem cells isolated by Dr.
(ATHX) announced die publication of articles in two journals that describe the potential for multipotent adult progenitor cells (MAPCs
), or MultiStem cells, to provide benefit in autoimmune disease and in peripheral vascular disease (PVD), respectively.
MultiStem is a proprietary medication made from a patented class of early adult stem cells called Multipotent Adult Progenitor Cells or MAPCs
that are obtained from the bone marrow.